CLINICAL TRIALS PROFILE FOR OPDIVO
✉ Email this page to a colleague
All Clinical Trials for OPDIVO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01585194 ↗ | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Recruiting | Bristol-Myers Squibb | Phase 2 | 2012-11-01 | The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells. |
| NCT01585194 ↗ | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2012-11-01 | The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells. |
| NCT01585194 ↗ | Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma | Recruiting | M.D. Anderson Cancer Center | Phase 2 | 2012-11-01 | The goal of this clinical research study is to learn if ipilimumab and nivolumab can help to control uveal melanoma. Ipilimumab is designed to increase the immune system's ability to fight cancer. Nivolumab is an antibody (a protein that attacks foreign cells) that is designed to allow the body's immune system to work against tumor cells. |
| NCT01592370 ↗ | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Active, not recruiting | Janssen, LP | Phase 1/Phase 2 | 2012-08-02 | The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma. |
| NCT01592370 ↗ | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Active, not recruiting | Bristol-Myers Squibb | Phase 1/Phase 2 | 2012-08-02 | The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma. |
| NCT01703949 ↗ | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2013-03-20 | This phase II pilot trial studies how well brentuximab vedotin with or without nivolumab works in treating patients with CD30+ lymphoma that has come back after a period of improvement or does not respond to treatment. Biological therapies, such as brentuximab vedotin, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as nivolumab may interfere with the ability of tumor cells to grow and spread. Giving brentuximab vedotin with or without nivolumab may work better in treating patients with CD30+ lymphoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OPDIVO
Condition Name
Clinical Trial Locations for OPDIVO
Trials by Country
Clinical Trial Progress for OPDIVO
Clinical Trial Phase
Clinical Trial Sponsors for OPDIVO
Sponsor Name
